JP2014517025A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014517025A5 JP2014517025A5 JP2014515214A JP2014515214A JP2014517025A5 JP 2014517025 A5 JP2014517025 A5 JP 2014517025A5 JP 2014515214 A JP2014515214 A JP 2014515214A JP 2014515214 A JP2014515214 A JP 2014515214A JP 2014517025 A5 JP2014517025 A5 JP 2014517025A5
- Authority
- JP
- Japan
- Prior art keywords
- glioblastoma
- compound
- modified
- hydrogen
- carbonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC(C)(C(CCC=C1*2)C11Oc3c2c(O*)c(C=CC(C)(C*)O2)c2c3CC=C(C)C)OC1(CC=C(C)C(N)=O)C(O)=O Chemical compound CC(C)(C(CCC=C1*2)C11Oc3c2c(O*)c(C=CC(C)(C*)O2)c2c3CC=C(C)C)OC1(CC=C(C)C(N)=O)C(O)=O 0.000 description 3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161497215P | 2011-06-15 | 2011-06-15 | |
| US61/497,215 | 2011-06-15 | ||
| PCT/EP2012/061485 WO2012172069A1 (en) | 2011-06-15 | 2012-06-15 | Glioblastoma inhibiting compounds and their use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014517025A JP2014517025A (ja) | 2014-07-17 |
| JP2014517025A5 true JP2014517025A5 (enExample) | 2016-03-31 |
| JP6228113B2 JP6228113B2 (ja) | 2017-11-08 |
Family
ID=46319762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014515214A Expired - Fee Related JP6228113B2 (ja) | 2011-06-15 | 2012-06-15 | グリア芽腫阻害化合物およびその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9573960B2 (enExample) |
| EP (1) | EP2721035B1 (enExample) |
| JP (1) | JP6228113B2 (enExample) |
| CN (1) | CN103764659A (enExample) |
| AU (1) | AU2012268984B2 (enExample) |
| BR (1) | BR112013032360A2 (enExample) |
| CA (1) | CA2838945A1 (enExample) |
| CL (1) | CL2013003563A1 (enExample) |
| IL (1) | IL229767A0 (enExample) |
| MX (1) | MX340816B (enExample) |
| PH (1) | PH12013502530A1 (enExample) |
| RU (1) | RU2014101070A (enExample) |
| WO (1) | WO2012172069A1 (enExample) |
| ZA (1) | ZA201309365B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014023329A1 (en) | 2012-08-06 | 2014-02-13 | Life And Brain Gmbh | Niclosamide and its derivatives for use in the treatment of solid tumors |
| WO2016210289A1 (en) | 2015-06-24 | 2016-12-29 | Duke University | Chemical modulators of signaling pathways and therapeutic use |
| EP3328495A4 (en) * | 2015-07-31 | 2019-01-16 | Swedish Health Services | METHOD AND COMPOSITIONS FOR CHARACTERIZING GLOBALBLASTOMA MULTIFORM TUMORS AND CANCER STEM CELLS |
| WO2017048800A1 (en) * | 2015-09-15 | 2017-03-23 | Swedish Health Services | Methods and panels of compounds for characterization of glioblastoma multiforme tumors and cancer stem cells thereof |
| CN105802928A (zh) * | 2016-03-30 | 2016-07-27 | 苏州偲聚生物材料有限公司 | 用于检测血清中mgmt抗体的多肽，检测器件和检测试剂盒 |
| CN105796549A (zh) * | 2016-04-22 | 2016-07-27 | 中国医学科学院基础医学研究所 | 藤黄酰胺用于制备治疗人神经胶质瘤的药物的用途 |
| CN107475213A (zh) * | 2016-06-08 | 2017-12-15 | 中国科学院苏州纳米技术与纳米仿生研究所 | 用于检测血清中mgmt抗体的多肽，检测器件和检测试剂盒 |
| WO2019178059A1 (en) | 2018-03-13 | 2019-09-19 | Georgetown University | ENHANCING CHEMOTHERAPY IN MEDULLOBLASTOMA AND GLIOBLASTOMA WITH HIGH BASAL p53 LEVELS |
| CN110433154A (zh) * | 2019-08-12 | 2019-11-12 | 昆明理工大学 | 藤黄酸的新用途 |
| WO2023183463A1 (en) * | 2022-03-23 | 2023-09-28 | University Of Cincinnati | Methods of potentiating temozolomide activity against glioblastoma cells |
| CN117538458B (zh) * | 2024-01-09 | 2024-03-29 | 中国医学科学院北京协和医院 | 同时定量分析14种单糖/二糖的液相色谱串联质谱分析方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000045165A1 (en) * | 1999-02-01 | 2000-08-03 | Cytovia, Inc. | Methods of identifying therapeutically effective antineoplastic agents with cultured cells having intact cell membranes and corresponding products |
| US6462041B1 (en) * | 1999-05-21 | 2002-10-08 | Cytovia, Inc. | Gambogic acid, analogs and derivatives as activators of caspases and inducers of apoptosis |
| JP3904364B2 (ja) | 2000-03-03 | 2007-04-11 | 独立行政法人科学技術振興機構 | 抗マラリア活性を有する新規化合物 |
| EP1300403A1 (en) | 2001-10-02 | 2003-04-09 | Aventis Pharma S.A. | Process for the manufacture of hypoxyxylerone derivatives |
| WO2008148008A1 (en) * | 2007-05-23 | 2008-12-04 | Emory University | High throughput bioassay for identifying selective trka receptor agonists, and gambogic amide, a selective trka agonist with neuroprotective activity |
| CN101289482B (zh) * | 2007-09-29 | 2011-08-31 | 辽宁利锋科技开发有限公司 | 藤黄酸苷衍生物和类似物及其制备方法和用途 |
| PA8851101A1 (es) * | 2008-12-16 | 2010-07-27 | Lilly Co Eli | Compuesto amino pirazol |
-
2012
- 2012-06-15 JP JP2014515214A patent/JP6228113B2/ja not_active Expired - Fee Related
- 2012-06-15 BR BR112013032360A patent/BR112013032360A2/pt not_active IP Right Cessation
- 2012-06-15 EP EP12728260.6A patent/EP2721035B1/en not_active Not-in-force
- 2012-06-15 RU RU2014101070/04A patent/RU2014101070A/ru not_active Application Discontinuation
- 2012-06-15 AU AU2012268984A patent/AU2012268984B2/en not_active Expired - Fee Related
- 2012-06-15 US US14/126,512 patent/US9573960B2/en not_active Expired - Fee Related
- 2012-06-15 MX MX2013014708A patent/MX340816B/es active IP Right Grant
- 2012-06-15 CN CN201280028960.8A patent/CN103764659A/zh active Pending
- 2012-06-15 CA CA2838945A patent/CA2838945A1/en not_active Abandoned
- 2012-06-15 WO PCT/EP2012/061485 patent/WO2012172069A1/en not_active Ceased
- 2012-06-15 PH PH1/2013/502530A patent/PH12013502530A1/en unknown
-
2013
- 2013-12-02 IL IL229767A patent/IL229767A0/en unknown
- 2013-12-11 ZA ZA2013/09365A patent/ZA201309365B/en unknown
- 2013-12-12 CL CL2013003563A patent/CL2013003563A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014517025A5 (enExample) | ||
| Kim et al. | HIF2α cooperates with RAS to promote lung tumorigenesis in mice | |
| Li et al. | AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis | |
| Tse et al. | Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality | |
| RU2602185C2 (ru) | Биомаркеры для терапии на основе ингибитора hedgehog | |
| RU2014101070A (ru) | Ингибирующие глиобластому соединения и их применение | |
| ES2788952T3 (es) | Método y kits para identificación de inhibidores CDK9 para el tratamiento de cáncer | |
| US20160222467A1 (en) | Phosphatidylinositol-3-kinase pathway biomarkers | |
| Sun et al. | Diverse roles of C-terminal Hsp70-interacting protein (CHIP) in tumorigenesis | |
| Labrecque et al. | The retinoblastoma protein regulates hypoxia-inducible genetic programs, tumor cell invasiveness and neuroendocrine differentiation in prostate cancer cells | |
| Linder et al. | EGFR is required for FOS‐dependent bone tumor development via RSK2/CREB signaling | |
| US12410152B2 (en) | Oxazole and thioazole-type cullin ring ubiquitin ligase compounds and uses thereof | |
| Zhong et al. | Bioluminescent imaging of HPV-positive oral tumor growth and its response to image-guided radiotherapy | |
| Kechele et al. | Orphan Gpr182 suppresses ERK-mediated intestinal proliferation during regeneration and adenoma formation | |
| Shang et al. | FAK kinase activity is required for the progression of c-MET/β-catenin-driven hepataocellular carcinoma | |
| US7531318B2 (en) | Screening of agents for activity against ischemic myocardial insults | |
| Chung et al. | Comparison of liver oncogenic potential among human RAS isoforms | |
| JP2010514421A5 (enExample) | ||
| Assefnia et al. | Trp63 is regulated by STAT5 in mammary tissue and subject to differentiation in cancer | |
| JP5481619B2 (ja) | デノボ癌を自然発症するモデル動物及びその用途 | |
| EP2027294A2 (en) | Cooperating oncogenes in cancer | |
| US20060162000A1 (en) | Development and use of a new orthotopic, genetically tractable non-human animal model for liver cancer | |
| JP2015506665A5 (enExample) | ||
| Ivanisevic et al. | Increased dosage of wild-type KRAS protein drives KRAS-mutant lung tumorigenesis and drug resistance | |
| DeWitt et al. | The effect of 1, 25 dihydroxyvitamin D3 treatment on the mRNA levels of β catenin target genes in mice with colonic inactivation of both APC alleles |